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Biochemical monitoring of mTOR inhibitor–based immuno-
suppression following kidney transplantation: A novel ap-
proach for tailored immunosuppressive therapy.
Background. Immunosuppressive therapy with the mam-
malian target of rapamycin (mTOR) inhibitors requires a fine
balance between allograft maintenance and drug-related side
effects.
Methods. In this study we examined the feasibility of moni-
toring TOR inhibitor–based immunosuppression by assessment
of the phosphorylation status at the Thr389 site of the p70S6 ki-
nase in peripheral blood mononuclear cells (PBMCs). At total
of 36 patients with renal transplants and 8 healthy controls were
enrolled.
Results. We found that sirolimus treatment was associated
with a pronounced inhibition of p70S6 kinase phosphoryla-
tion, as compared to healthy donors or otherwise immunosup-
pressed patients. In sirolimus-treated patients, phosphorylation
of the p70S6 kinase was significantly inhibited when sirolimus
trough levels were > 6 ng/mL. In contrast, for trough levels
<6 ng/mL, the degree of inhibition of p70S6 kinase phospho-
rylation showed a high degree of interindividual variability. We
recorded a total of five clinical relevant rejection episodes in this
patient category. Intriguingly, rejecters uniformly maintained a
high degree of phosphorylation independent of the sirolimus
trough level whereas non-rejecters showed a significant inhibi-
tion of phosphorylation.
Conclusion. Therefore, the phosphorylation status of the
p70S6 kinase appears to provide more relevant information
on the desired effect of sirolimus in target cells as compared
to trough level measurements. Moreover, this assay provides
an opportunity to safely titer down sirolimus levels to avoid
overimmunosuppression and, on the other hand, to identify pa-
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tients with insufficient TOR inhibitor therapy that are at risk
for rejection.
The recent introduction of sirolimus into clinical trans-
plantation allowed transplant physicians to develop vari-
ous immunosuppressive strategies to provide adequate
immunosuppression for the transplant recipient while
avoiding the nephrotoxic side effects associated with cal-
cineurin inhibitor therapy. Sirolimus forms a complex
with the FK-binding protein complex that binds with high
affinity to the mammalian target of rapamycin (mTOR).
This interaction causes dephosphorylation and inactiva-
tion of the p70S6 kinase, which, when activated, stimu-
lates the production of ribosomal components necessary
for protein synthesis and cell cycle progression. This ac-
tivity, which effectively blocks interleukin (IL)-2 stimula-
tion of lymphocyte division, is the basis for the successful
clinical use of sirolimus to prevent allograft rejection in
organ transplantation [1, 2]. Since sirolimus is a critical
dose drug with a low therapeutic index, under- or over-
dosing can lead to rejection or toxicity, respectively. In
renal transplant recipients, a significant association has
been observed between sirolimus trough concentrations
and both the occurrence and the severity of acute re-
jection. Moreover, sirolimus trough levels correlate with
the incidence of side effects such as wound healing prob-
lems, hyperlipidaemia, thrombocytopenia, or leukopenia
[3]. Currently, adjustment of the sirolimus dose entirely
relies on the sirolimus blood concentrations, which may
not necessarily correlate with the pharmacologic effects
of the drug on immune cells. Thus, the assessment of
direct drug effects in the target cells involved in the im-
mune response after organ transplantation may aid to op-
timize immunosuppressive therapy. Here we investigated
whether the actual functional efficacy of sirolimus-based
immunosuppression might be monitored more closely by
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Table 1. Patients’ characteristics
Healthy Otherwise immunosuppressed Sirlolimus-treated
individuals patients patients
Number of patients 8 12 24
Number of samples 8/8 12/12 7/7
28/14a
13/3b
Age years 37 ± 5 51 ± 8 47 ± 9
Male/female 6/2 9/3 14/10
Duration of immunosuppression months 18 ± 22 (8) 6 ± 16 (1)
Sirolimus trough level ng/mL 5.4 ± 2.7
Rejection episodes 4 × Banff class 4IA in 3 patients
1 × Banff class 3 in 1 patient
Immunosuppression 1 × Tacrolimus + MMF + ST 11 × Sirolimus + MMF + ST
2 × Cyclosporine A + MMF + ST 3 × Cyclosporine A + sirolimus + ST
1 × Cyclosporine A + azathioprine + ST 4 × Tacrolimus + sirolimus + ST
7 × MMF + (5×) ST 6 × Sirolimus + (3×) ST
1 × Aazathioprine
MMF is mycophenolate mofetil; ST is steroids. Data are given as mean ± SD (median).
a Two separate samples were drawn at different time points (>14 days apart).
b Longitudinal measurements were performed in three patients at multiple time points (see Fig. 3).
assessing the phosphorylation status of the p70S6 kinase
at the Thr389 site, which is specifically phosphorylated by
mTOR [2, 4].
METHODS
For the present study, peripheral blood samples were
collected from eight healthy volunteers and 36 patients at
various time points following transplantation. Patients’
characteristics are shown in Table 1. Of these patients,
24 patients were treated with sirolimus, whereas 12 pa-
tients were immunosuppressed with drugs other than
sirolimus. In sirolimus-treated patients we aimed to reach
trough levels of 4 to 7 ng/mL. In combination with
sirolimus mycophenolate mofetil (MMF) was given in a
fixed dose of 2 × 0.75 g/day. In patients who did not re-
ceive sirolimus, immunosuppression was titrated to reach
trough levels of 5 to 8 ng/mL for tacrolimus and C2 val-
ues of 800 to 1000 ng/mL for cylosporine. MMF was ei-
ther given in a fixed dose of 2 × 1g/day or controlled
by mycophenolic acid (MPA) trough level monitoring
(target level 2 to 6 lg/mL). Informed consent was ob-
tained from all participating individuals and peripheral
blood mononuclear cells (PBMCs) were isolated as de-
scribed elsewhere [5]. In contrast to previous work by
Gallant and Yatscoff [6], where total p70S6 kinase ac-
tivity was assessed, we quantified phosphorylation of the
p70S6 kinase at the mTOR-specific Thr389 site (known
site of molecular activation) by Western blot analysis as
described elsewhere [5, 7, 8]. Sirolimus trough levels were
measured by high-performance liquid chromatography
(HPLC) as part of the clinical routine.
RESULTS
To determine whether phosphorylation of the p70S6
kinase at the Thr389 site can serve as a biomarker for
mTOR inhibition, we assessed the phosphorylation sig-
nal of healthy volunteers and compared the phosphory-
lation status with that observed for transplanted patients
who received immunosuppression with or without TOR
inhibitors. In all tested healthy volunteers, we found a
robust and homogenous phosphorylation signal at the
Thr389 site of the p70S6 kinase (Fig. 1A). In this group, the
intraindividual (data not shown) and the interindividual
(Fig. 1B) variability of the phosphorylation was small, in-
dicating that p70S6 kinase phosphorylation is a constant
variable among healthy individuals. In transplanted pa-
tients who did not receive sirolimus for immunosuppres-
sion, the mean phosphorylation was similar to healthy
controls. In contrast to healthy controls, however, the
interindividual variability was fairly large in this group,
suggesting that the immune response in some of these
patients may have been activated. Sirolimus-treated pa-
tients, according to the principal mechanism of TOR
inhibitors, generally showed a significantly reduced phos-
phorylation of the p70S6 kinase. However, when we sep-
arately analyzed the phosphorylation status of rejectors
during a clinically relevant rejection episode in compari-
son to patients without rejections, we found, that rejecters
uniformly had maintained a high degree of phosphoryla-
tion, while nonrejecters presented with a significant in-
hibition of phosphorylation. Since all clinical rejections
occurred within the first 3 months in patients receiving
a sirolimus-dominated immunosuppression [sirolimus +
MMF + steroids (ST)], these data suggest that lack of in-
hibition of the p70S6 kinase phosphorylation may reflect
insufficient immunosuppression in these patients.
Accordingly, we have been able to demonstrate that
measuring the phosphorylation of the p70S6 kinase is an
applicative method to monitor TOR inhibitor treatment
effects. To investigate whether the phosphorylation sta-
tus of the p70S6 kinase is a more reliable indicator of
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Fig. 1. Immunosuppression with sirolimus
(SRL) inhibits phosphorylation of the p70S6
kinase (p70S6K) at the Thr389 site. (A)
Representative Western blot illustrating the
phosphorylation status in healthy individuals,
otherwise immunosuppressed patients, and
sirolimus-treated patients. (B) Quantification
of the Western blot analyses reveals that the
p70S6 kinase in healthy individuals and oth-
erwise immunosuppressed patients, respec-
tively, is strongly phosphorylated. Sirolimus
treatment significantly decreases the degree
of phosphorylation of the p70S6 kinase. A
high phosphorylation status under sirolimus
therapy indicates insufficient mammalian tar-
get of rapamycin (mTOR) inhibition. Under
these conditions clinically relevant rejections
can be observed. Data are given as percent
of healthy controls. Data are given as me-
dian with upper and lower quartile (bars).
Whiskers indicate the range of the data. Dots
illustrate outliers.
mTOR inhibition as compared to peripheral blood levels
of TOR inhibitors, we next investigated the association
between the phosphorylation status of the p70S6 kinase
and the corresponding sirolimus trough levels. Interest-
ingly, sirolimus levels required for sufficient inhibition
of p70S6 kinase phosphorylation varied considerably be-
tween patients. In patients with sirolimus trough levels
equal or above 6 ng/mL, p70S6 kinase phosphorylation
was constantly inhibited (Fig. 2). In contrast, in patients
with sirolimus trough levels below 6 ng/mL, p70S6 ki-
nase phosphorylation was extremely variable. In a sub-
group of patients, phosphorylation of the p70S6 kinase
was inhibited (<60% of control) despite the relatively
low sirolimus trough levels (Fig. 2, lower left quadrant). In
some of these individuals, trough levels as low as 2 ng/mL
completely inhibited phosphorylation. In other patients,
however, sirolimus trough levels below 6 ng/mL were
not sufficient to adequately (<60% of control) suppress
phosphorylation of the p70S6 kinase (Fig. 2, upper left
quadrant). Strikingly, all sirolimus-treated patients with
clinical allograft rejection exclusively showed high phos-
phorylation values (>60% of control) and a low sirolimus
trough level (<6 ng/mL) at the time of rejection. On the
other hand, if phosphorylation was significantly inhibited
despite relatively low sirolimus trough levels, no rejection
episodes occurred. At a cutoff value of 60% phosphory-
lation relative to control, we found a sensitivity of 99%
and a specificity of 73% for the prediction of rejection
episodes. Consistently, receiver operating characteristics
curve analysis revealed a significantly greater area under
the curve for the phosphorylation status of the p70S6 ki-
nase [0.88 (95% CI 0.78-0.98)] as compared to the area
under the curve for the sirolimus blood levels [0.67 (95%
CI 0.50-0.84)] (P < 0.05).
To envision the dynamics of changes of the phospho-
rylation status of the p70S6 kinase, we additionally per-
formed longitudinal measurements in three individual
patients within the first 3 months following transplanta-
tion. All patients received a TOR inhibitor–based im-
munosuppression (sirolimus + MMF + ST). In these
patients, adjustment of the sirolimus dose was followed
by changes in the phosphorylation of the p70S6 kinase
(Fig. 3). Furthermore, it appears that relatively small
changes in the trough levels can lead to a marked change
in the phosphorylation status. These data virtually ex-
clude a linear relationship between the inhibition of phos-
phorylation and the measured sirolimus trough levels.
Thus, determining the phosphorylation status might be
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Fig. 2. Association between sirolums trough
levels and the phosphorylation status of the
p70S6 kinase (p70S6K). The phosphoryla-
tion status (y axis) was plotted against the
sirolimus trough level (x axis). Even at rela-
tively low sirolimus trough levels (<6 ng/mL),
phosphorylation was significantly reduced in
50% of the cases. Clinical rejections occurred
in patients with low sirolimus trough level
and insufficient inhibition of the p70S6 ki-
nase phosphorylation, indicating underim-
munosuppression in these individuals (upper
left quadrant). Black dots indicate patients
with rejections (either Banff class 4IA or
Banff class 3). Identical numbers indicate lon-
gitudinal measurements in an individual pa-
tient (1 to 3 multiple, 4 to 17 double, 18 to 24
single measurements).
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Fig. 3. Longitudinal assessment of the p70S6
kinase (p70S6K) phosphorylation in three in-
dividual patients. The phosphorylation sta-
tus (y axis) was plotted against the time af-
ter transplantation (x axis). Numbers above
or below the symbols indicate the sirolimus
(SRL) trough level in ng/mL at the individual
time point. MMF is mycophenolate mofetil;
ST is steroids.
more adequate than relying on sirolimus trough levels to
optimize the TOR inhibitor dosing.
DISCUSSION
Currently, monitoring of immunosuppression is based
on pharmacokinetic data obtained by measuring blood
levels of the drug, which do not necessarily predict clinical
efficacy or toxicity in an individual patient. Importantly,
however, trough levels were derived from clinical stud-
ies and were defined as the levels when the vast majority
of patients displayed stable graft function with minimal
rejection episodes. In order to provide sufficient immuno-
suppression and effectively prevent allograft rejection in
the majority of patients, target trough levels are usually
set rather high. Beside an increased rate of direct side
effects, these high trough levels encounter for all the neg-
ative consequences of overimmunosuppression such as
an increased frequency of infections or malignancy. On
the other hand, in case of severe side effects, transplant
physicians are usually obliged to individually lower drug
levels based on graft function which may bear the risk of
allograft rejection. At present, recommended trough lev-
els for sirolimus range from 5 to 15 ng/mL [9]. However,
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a recent study by van Hooff et al [10] demonstrated that
sirolimus in combination with tacrolimus can effectively
prevent rejection at far lower trough levels (∼1 ng/mL).
Studies trying to determine the lowest possible level of
immunosuppression are helpful, but may be hampered
by marked interindividual differences.
In the present study, we used the phosphorylation sta-
tus of the p70S6 kinase at the Thr389 site as a biomarker
for mTOR inhibition. In contrast to conventional blood
level monitoring, where sirolimus bound to erythrocytes
is measured in whole blood samples, our approach consid-
ers the individual and functional effect of sirolimus treat-
ment in the target compartment, namely the lymphocytic
cell population. Importantly, this assay is also capable to
detect sufficient mTOR inhibition even when the mTOR
pathway is preactivated by an ongoing immune response.
Indeed, based on our Western blot analyses this might
well be the case during rejection episodes.
Based on our data, a sirolimus trough level equal
or above 6 ng/mL were in all patients tested sufficient
to inhibit p70S6 kinase phosphorylation below 60% of
control. In patients with sirolimus trough levels below
6 ng/mL, this assay allows to differentiate between pa-
tients who still have a pharmacologic effect, namely, suf-
ficient suppression of the phosphorylation, and patients
with a sirolimus dosing that is too low for a sufficient
pharmacologic effect. Not surprisingly, exactly this group
of patients showed clinically relevant rejection episodes.
Since our analyses lack standardization and patients were
not balanced in terms of rejection, immunosuppressive
strategies, and time after transplantation, we should not
describe the rejection as a direct consequence of insuf-
ficient suppression of p70S6 kinase phosphorylation in
these patients. Indeed, this was not the primary aim of
the present study rather than to demonstrate that an as-
say which considers individual drug effects on the target
cell population may allow transplant physicians to more
precisely adjust immunosuppressive therapy according
to individual needs and hence avoid over- and underim-
munosuppression, respectively.
At present, we do not know the exact in vivo dynam-
ics of the phosphorylation degree of the p70S6 kinase.
It could either reflect the current immunosuppressive
state or summarize the immunosuppressive activity of a
longer period of time. However, individual longitudinal
measurements and our preclinical studies indicate that
changes of the phosphorylation of the Thr369 site of the
p70S6 kinase respond rather rapidly to changes in the
TOR inhibitor dosing.
Since clinical rejection is a multifactorial event and
is determined by the net immunosuppression of all im-
munosuppressive agents used, we cannot predict rejec-
tion episodes with this assay, especially when sirolimus
is additively used in combined therapy with tacrolimus
or cyclosporine. However, we were able to demonstrate
that the pharmacologic goal of blocking mTOR is insuf-
ficiently reached, only when phosphorylation is below
60%. Therefore, in immunosuppressive regimens which
are based on an mTOR inhibitor as the leading substance,
a high degree of phosphorylation (>60%) may identify
patients at risk for clinical allograft rejection irrespective
of the sirolimus trough level.
Taken together, the preliminary data of this study indi-
cate for the first time that assessing the phosphorylation
status of the p70S6 kinase can be used for monitoring
a TOR inhibitor treatment. This study further suggests
that sirolimus trough levels equal or above 6 ng/mL are
rather safe with respect to prevention of allograft rejec-
tion. In contrast, in patients with sirolimus trough levels
below 6 ng/mL, the individual drug response can be de-
termined by assessing the phosphorylation status of the
p70S6 kinase. Since this assay indirectly measures mTOR
activity, it should also be useful for monitoring other
TOR inhibitors such as RAD001 or CCI-779. Therefore,
this assay may serve as a novel tool for tailoring TOR
inhibitor therapy, not only in transplantation, but also
in oncologic trials, where TOR inhibitors are currently
being tested as antiproliferative agents. Apparent limi-
tations of this study are its uncontrolled nature, the het-
erogeneous study population, and the nonstandardized
follow-up. To prospectively test this approach in a larger
study population with a standardized follow-up, we are
currently translating this principal idea to an enzyme-
linked immunosorbent assay (ELISA)-based technology.
Once established, we will verify the present, truly prelim-
inary data in a randomized trial in renal transplantation
with an early conversion protocol from cyclosporine plus
MMF to sirolimus plus MMF.
ACKNOWLEDGMENTS
The authors thank the colleagues of the Transplantation Center
Grosshadern, especially Wolf-Dieter Illner, Helmut Arbogast, and
Walter Land, for their support. We are grateful to Michael Eder and
Michael Bru¨ckel for their excellent technical assistance. This research
was supported by a grant from the Wilhelm Sander-Stiftung (Nr. 2003.
133.1) and the Fo¨FoLe Research Program of the University of Munich.
Reprint requests to Dr. Markus Guba, Department of Surgery, Uni-
versity of Munich, Klinikum Grosshadern, Marchioninistr. 15, 81377
Mu¨nchen, Germany.
E-mail: markus.guba@med.uni-muenchen.de
REFERENCES
1. KREIS H, OBERBAUER R, CAMPISTOL JM, et al: Long-term benefits
with sirolimus-based therapy after early cyclosporine withdrawal. J
Am Soc Nephrol 15:809–817, 2004
2. SEHGAL SN: Rapamune (RAPA, rapamycin, sirolimus): Mechanism
of action immunosuppressive effect results from blockade of signal
transduction and inhibition of cell cycle progression. Clin Biochem
31:335–340, 1998
2598 Hartmann and Schmid et al: Tailored mTOR inhibitor–based immunosupression
3. FISCHEREDER M, KRETZLER M: New immunosuppressive strategies
in renal transplant recipients. J Nephrol 17:9–18, 2004
4. DUFNER A, THOMAS G: Ribosomal S6 kinase signaling and the con-
trol of translation. Exp Cell Res 253:100–109, 1999
5. BOULAY A, ZUMSTEIN-MECKER S, STEPHAN C, et al: Antitumor effi-
cacy of intermittent treatment schedules with the rapamycin deriva-
tive RAD001 correlates with prolonged inactivation of ribosomal
protein S6 kinase 1 in peripheral blood mononuclear cells. Cancer
Res 64:252–261, 2004
6. GALLANT HL, YATSCOFF RW: P70 S6 kinase assay: A pharmaco-
dynamic monitoring strategy for rapamycin; assay development.
Transplant Proc 28:3058–3061, 1996
7. PERALBA JM, DEGRAFFENRIED L, FRIEDRICHS W, et al: Pharmaco-
dynamic evaluation of CCI-779, an inhibitor of mTOR, in cancer
patients. Clin Cancer Res 9:2887–2892, 2003
8. SEELIGER H, GUBA M, KOEHL GE, et al: Blockage of 2-deoxy-D-
ribose-induced angiogenesis with rapamycin counteracts a thymi-
dine phosphorylase-based escape mechanism available for colon
cancer under 5-fluorouracil therapy. Clin Cancer Res 10:1843–1852,
2004
9. KAHAN BD: Sirolimus: A ten-year perspective. Transplant Proc
36:71–75, 2004
10. VAN HOOFF JP, SQUIFFLET JP, WLODARCZYK Z, et al: A prospective
randomized multicenter study of tacrolimus in combination with
sirolimus in renal-transplant recipients. Transplantation 75:1934–
1939, 2003
